Curonix LLC has reached a significant milestone in chronic pain management with the recent reimbursement updates for its Freedom® Peripheral Nerve Stimulator (PNS) System. Aetna has officially recognized this innovative device as a covered treatment for members suffering from intractable neuropathic pain, contingent on medical necessity and adherence to specific criteria. This recognition by Aetna, alongside additional coverage from Health Alliance Plan of Michigan, Select Health, Sentara Health Plan, and University of Utah Health Plans, expands access to a total of 27 million covered lives across the United States, marking a pivotal moment for non-opioid pain management solutions.

The implications of this development are substantial for the longevity and healthspan research community. With an increasing number of payers acknowledging peripheral nerve stimulation as a viable alternative to traditional pain therapies, there is a clear shift toward embracing minimally invasive, non-opioid treatments. The Freedom PNS System, which operates without an implanted battery and utilizes high-frequency electromagnetic coupling, represents a significant advancement in the realm of pain management technologies. As more patients gain access to this clinically validated therapy, the potential for improved quality of life and reduced reliance on opioids could reshape treatment paradigms in chronic pain management.

For professionals in the field, this milestone underscores the importance of advocating for innovative therapies that address chronic pain without the risks associated with opioid use. As payer recognition continues to grow, it may catalyze further research and development in non-opioid treatments, ultimately enhancing therapeutic options for patients and contributing to the broader goals of longevity and healthspan improvement.

Source: globenewswire.com